热门资讯> 正文
内部收购后雅塔拉股价上涨
2025-07-23 03:02
- Atara生物医药(ATRA) 0
- 纳比特(NA) 0
- 盛大科技(SDA) 0
- Shares of Atara Biotherapeutics (NASDAQ:ATRA) spiked for the second straight session on Tuesday following an insider purchase of more than 19K company shares by Panacea Innovation Ltd., an investor with over 10% ownership in the California-based biotech.
- According to a regulatory filing on Monday, the British venture capital firm purchased a little over 19.3K ATRA shares on July 17 for nearly $9.64 each in a transaction worth ~$186.4K.
- Panacea Innovation recorded a holding of 1.35M ATRA shares before the purchase, implying ~23% of outstanding shares of the company’s common stock as of May 9, 2025.
- The transaction comes after Atara (NASDAQ:ATRA) shares climbed more than 25% over the past 12 months despite the FDA’s rejection of its immunotherapy candidate, Ebvallo, and a clinical hold that impacted several of its development programs early this year.
More on Atara Biotherapeutics
- Atara Biotherapeutics prices $16M public offering
- Atara Biotherapeutics to reduce workforce by 30%
- Seeking Alpha’s Quant Rating on Atara Biotherapeutics
- Historical earnings data for Atara Biotherapeutics
- Financial information for Atara Biotherapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
